Investing & trading with exchange-traded funds (ETFs) and closed-end funds (CEFs). Strategies & analysis but no buy or sell recommendations.
Visit SeekingAlpha ETFs
China Biotech Week in Review: Deals and Drugs
Posted on June 15, 2008
Last week, the news item that could have the most profound effect on the China biomedical world, did not paradoxically involve a China biomedical company. The third largest pharmaceutical company in Japan, Daiichi Sankyo [TSE: 4568.JP], announced its intention to buy a majority stake in Ranbaxy [NSE/BSE: Ranbaxy/500359], the generic drug maker that is the largest pharmaceutical company in India (see story). The purchase price could reach as much as $4.6 billion. A comparison between India and China drug markets turns up many differences the Indian firms are more mature with larg...
Original article link
Subscribe to SeekingAlpha ETFs